Edurant Ped Tablet, For Suspension
NDC Package 59676-280-90

11-digit billing NDC: 59676028090 · Billing unit: EA · 90 EA per package

Package Information

Edurant Ped (rilpivirine hydrochloride) tablets is eDURANT and EDURANT PED are contraindicated for coadministration with the drugs in Table 2 for which significant decreases in rilpivirine plasma concentrations may occur due to CYP3A enzyme induction or gastric pH increase, which may result in loss of virologic response and possible resistance to EDURANT or EDURANT PED or to the class of NNRTIs [see Drug Interactions (7)and Clinical Pharmacology (12.3)]. This formulation utilizes a tablet, for suspension delivery system. Marketed by Janssen Products, Lp, this product is identified by NDC 59676-280 and is authorized under FDA application NDA219016.

Identification & Billing

NDC Package Code
59676-280-90
Package Description
9 BLISTER PACK in 1 CARTON / 10 TABLET, FOR SUSPENSION in 1 BLISTER PACK (59676-280-01)
Product Code
11-Digit Billing Format
59676028090
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
90 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Edurant Ped
Non-Proprietary Name
Rilpivirine Hydrochloride
Substance Name
Rilpivirine Hydrochloride
Dosage Form
Tablet, For Suspension - A tablet that forms a suspension when placed in a liquid (formerly referred to as a ‘dispersible tablet’).
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
EDURANT and EDURANT PED are contraindicated for coadministration with the drugs in Table 2 for which significant decreases in rilpivirine plasma concentrations may occur due to CYP3A enzyme induction or gastric pH increase, which may result in loss of virologic response and possible resistance to EDURANT or EDURANT PED or to the class of NNRTIs [see Drug Interactions (7)and Clinical Pharmacology (12.3)] . Table 2: Drugs That are Contraindicated with EDURANT and EDURANT PEDDrug ClassContraindicated Drugs in ClassClinical CommentAnticonvulsantsCarbamazepine Oxcarbazepine Phenobarbital Phenytoin Potential for significant decreases in rilpivirine plasma concentrations due to CYP3A enzyme induction, which may result in loss of virologic response.AntimycobacterialsRifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal ProductsSt. John's wort ( Hypericum perforatum) Proton Pump Inhibitorse.g., Esomeprazole Lansoprazole Omeprazole Pantoprazole Rabeprazole Potential for significant decreases in rilpivirine plasma concentrations due to gastric pH increase, which may result in loss of virologic response.

Regulatory & Marketing

Labeler Name
Janssen Products, Lp
Product Type
Human Prescription Drug
FDA Application #
NDA219016
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-15-2024
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 59676-280-90 identifies a specific commercial package of 9 blister pack in 1 carton / 10 tablet, for suspension in 1 blister pack (59676-280-01) of Edurant Ped, a human prescription drug labeled by Janssen Products, Lp. This product is billed for "EA" each discreet unit and contains an estimated amount of 90 billable units per package. This tablet, for suspension is formulated for oral use and contains rilpivirine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Janssen Products, Lp on March 15, 2024. The current certification is valid through December 31, 2026.

How is this Janssen Products, Lp product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 59676028090. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
59676-280-90
11-Digit CMS (5-4-2)
59676-0280-90

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.